Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONITORA: Individualized Adalimumab Tapering Strategy in Rheumatoid Arthritis
NCT06528431Phase 4Recruiting
- Sponsor
- CHU Saint-Etienne
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (3 arms), sponsored by CHU Saint-Etienne. Primary endpoint: Rheumatoid arthritis flare-up at 15 months. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06528431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528431.